FDA Approves Icotyde: J&J's Once-Daily Psoriasis Pill That Rivals Tremfya and Skyrizi in a $100,000-a-Year Market
FDA approves Icotyde, J&J’s once-daily psoriasis pill, offering an oral alternative to costly injectable drugs like Tremfya and Skyrizi.
